Divi's Laboratories (DIVISLAB) Fundamentals 2026 — P/E 76.3x, Revenue Analysis | SniperIQ
Divi's Laboratories (DIVISLAB) is a India-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₹1.96 Lakh Crore, trading at ₹7386.75 on the BSE. This SniperIQ fundamentals page covers Divi's Laboratories's valuation (P/E 76.3x, P/B 11.7x), profitability (net margin 24.3%), revenue (₹10,560 Crore in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Divi's Laboratories's market cap?
Divi's Laboratories (DIVISLAB) has a market capitalization of approximately ₹1.96 Lakh Crore, trading at ₹7386.75 on the BSE. Market cap moves with the live share price.
What is Divi's Laboratories's P/E ratio?
Divi's Laboratories's trailing twelve-month P/E ratio is 76.3x, with a price-to-book (P/B) of 11.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Divi's Laboratories?
Divi's Laboratories runs a net profit margin of 24.3%, a gross margin of 52.1%, and an operating margin of 28.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Divi's Laboratories generate?
Divi's Laboratories reported revenue of ₹10,560 Crore for fiscal year 2026, with net income of ₹2,568 Crore and earnings per share (EPS) of 96.75. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Divi's Laboratories pay a dividend?
Divi's Laboratories offers a trailing dividend yield of about 0.4%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Divi's Laboratories financially healthy?
Divi's Laboratories carries a debt-to-equity ratio of 0.00x and a current ratio of 5.43x, with a market beta of 0.22. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Divi's Laboratories a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Divi's Laboratories (DIVISLAB) the key facts are: market cap ₹1.96 Lakh Crore, P/E 76.3x, revenue ₹10,560 Crore, 52-week range 5637.5-7437.65. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Divi's Laboratories's full fundamentals live
Get Divi's Laboratories's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.